President Emmanuel Macron of France has tested positive for the coronavirus, the French presidency said on Thursday, just as his government was trying to lift lockdown restrictions before Christmas and avoid another wave of infections.
“This diagnosis was established after a RT-PCR test that was carried out as soon as the first symptoms appeared,” a statement from the presidency said. It did not reveal what those symptoms were and when they first appeared.
Mr. Macron will work in isolation for the next seven days, the statement added. The office of Jean Castex, the country’s prime minister, said that he would also work from isolation because of his recent proximity with Mr. Macron.
Mr. Macron, 42, is not known to suffer from any medical problems. But the health of French presidents is traditionally a closely guarded secret, and France’s 24-hour news channels immediately began speculating on Thursday morning about how sick he might be.
Mr. Macron’s positive test has also affected other leaders across the continent, since he met with several foreign and domestic officials in the past week, including at the European Council in Brussels and in meetings with Prime Ministers Pedro Sánchez of Spain and António Costa of Portugal. Mr. Sánchez’s office said on Thursday that he would self-isolate until Dec. 24, 10 days after his last meeting with Mr. Macron, and would also be tested for the virus.
Mr. Macron also held a weekly meeting with his cabinet members on Wednesday, but the French presidency said that the officials were distanced and wore masks.
Several of his ministers tested positive for the virus last spring. And his wife, Brigitte Macron, isolated herself for several days a few months ago after being in close contact with an infected person.
Until now, Mr. Macron had managed to steer France through the pandemic without being forced into self-isolation because of potential exposure.
France has recently found itself at the heart of the virus’s second wave in Europe, forcing the country to delay loosening restrictions on movement and business. In October, it became the first nation in Europe to impose a second nationwide lockdown, which it is now starting to slowly lift ahead of Christmas.
French officials, like other leaders around Europe, were hopeful that vaccinations could begin in the coming days. Prime Minister Castex said on Wednesday that inoculations would start in the last week of this month, once the European and French authorities approve Pfizer-BioNTech’s vaccine, and that France would receive a first shipment of 1.16 million doses by the end of the year.
Ursula von der Leyen, the European Commission president, has urged countries in the bloc to begin inoculations on the same day, probably next week.
But the continent has struggled under the weight of a second wave of infections, leading leaders to reimpose widespread restrictions in recent weeks. In Germany, Chancellor Angela Merkel imposed a nationwide lockdown that will extend over Dec. 25, snuffing out hopes for a reprieve after the country’s beloved Christmas markets were shuttered this month. The Netherlands and the Czech Republic have also imposed lockdowns, and Italy is leaning toward one.
Constant Méheut and Megan Specia contributed reporting.
Word that the vaccine supply may be somewhat less scarce than thought came hours before the latest pandemic figures made one thing abundantly clear: Americans will need every drop.
By the end of the day on Wednesday, 3,607 new deaths from the virus has been reported in places as disparate as Los Angeles County, Calif., and Lee County, Va. That was nearly 500 more than the record set one week earlier. And new infections were put at more than 244,365, also a record.
It was, nevertheless, a day of hope as people across the country rolled up their sleeves and got shots.
In Seattle, one doctor who earlier this year was left near helpless as the virus marched unchecked through nursing homes was overcome with emotion as he got his vaccination. In New York, Mayor Bill de Blasio went to Elmhurst Hospital in Queens, an epicenter of death in March, to watch hospital workers getting shots.
“It doesn’t get better than this,” the mayor declared.
The discovery that there might be a little more vaccine than thought did not hurt.
As boxes of the newly authorized Pfizer-BioNTech vaccine began arriving around the country, hospital pharmacists discovered that the glass vials that were supposed to hold five doses contained enough for a sixth, or even a seventh. A little bit of “over fill” in vials that contain multiple doses of a drug is normal, they said, but this was different.
Nevertheless, it will be months before a meaningful number of people in the country can be vaccinated, and on Wednesday, warnings, not declarations of victory, were the order of the day.
“We are still at a dangerous and critical part of this pandemic, and tens of thousands of American lives are at stake, really, every week,” Adm. Brett P. Giroir, assistant secretary of health and human services, said on CNN’s “New Day.”
Admiral Giroir urged people to wear masks and avoid travel and crowds over the holidays.
“Until we get a few more months down the road, do your best,” he said. “Save lives, save American lives, save global lives, just by doing these simple measures. If you do that, we’re going to be in really good shape. But if you don’t, we’re going to have thousands of more casualties in this country that we can avoid.”
Dr. Anthony S. Fauci, the country’s top infection disease experts, was among those telling the country that even with a vaccine, this is not the moment for people to drop their guard.
“As wonderful as this is, because it’s been an extraordinary manifestation of the fruits of science done in a very rapid way, it’s also bittersweet,” he said.
Vice President Mike Pence and his wife, Karen Pence, will receive the Pfizer-BioNTech coronavirus vaccine on Friday, according to the White House, a move that the Trump administration says is intended to “promote the safety and efficacy of the vaccine and build confidence among the American people.”
The event, just days into the nation’s ambitious mass vaccination campaign, will take place at the White House, and the Pences will be joined by Surgeon General Jerome Adams, who will also receive the vaccine.
Dr. Anthony S. Fauci, the nation’s top infectious disease expert, said on Tuesday that he would recommend that President Trump and Mr. Pence get the vaccine, even though the president has already had Covid-19.
Dr. Fauci also said that it was his “strong recommendation” that President-elect Joseph R. Biden Jr. and Vice President-elect Kamala Harris receive a Covid-19 vaccine quickly.
“For security reasons, I really feel strongly that we should get them vaccinated as soon as we possibly can,” he said on “Good Morning America.” “You want him fully protected as he enters into the presidency in January.”
At a briefing on Tuesday, Kayleigh McEnany, the White House press secretary, said that Mr. Trump would “receive the vaccine as soon as his medical team determines it’s best,” but that he was not yet scheduled to do so.
For some elected officials and public figures, getting vaccinated may be a damned-if-you-do, damned-if-you-don’t proposition. On the one hand, doing so publicly could be useful as a show of confidence to the public. But with the vaccine in scarce supply, some in positions of power don’t want to be accused of jumping the line.
Patricia John was still in her nightgown this week in the West Virginia nursing home where she lives when a nurse hurried her out of her room to join a line that had formed in the hallway.
For the past nine months, she had spent most of her time alone in her room, at Sundale Rehabilitation and Long-Term Care in Morgantown, W.Va. But Tuesday was different as Mrs. John, 93, became one of the first nursing home residents in the United States to be vaccinated against the coronavirus.
“It was easier than what I have seen on television,” she said of the injection. “It was such a quick shot that no one should be afraid.”
An early round of coronavirus vaccinations is underway in a handful states this week ahead of the wide-scale federal program through CVS and Walgreens that is scheduled to roll out at facilities on Monday.
Facilities in West Virginia began inoculating residents on Tuesday. Ohio was also getting an early start, with Connecticut and Delaware expected to begin by the end of the week. In Florida, about 21,450 doses of the vaccines will be distributed to nursing homes this week to get a jump start on vaccinations.
The vaccines have been celebrated welcome as nursing homes have felt the brunt of Covid-19’s severity. At least a third of the country’s more than 305,000 deaths have been reported among residents and employees of nursing homes and other long-term care facilities for older adults, and more than 787,000 staff members and residents have become infected.
In interviews this week, nursing home administrators said they were unsure the number of residents who agreed to be vaccinated would mirror their general populations. They also warned that preventive measures put in place because of Covid-19 should not disappear just because residents were starting to be inoculated.
“We need to be just as careful as we were before vaccination until the risk of someone spreading the virus to them is diminished,” said Dr. Richard Feifer, the chief medical officer for Genesis HealthCare, one of the largest providers of long-term care with more than 325 facilities in 24 states.
The issue of obtaining consent from residents, including those unable to make the decision without family members’ input, has been a hurdle that has slowed vaccine rollout in some places.
With vaccinations being voluntary, its unlikely that a nursing facility would get 100 percent consent from residents, but officials said they hoped that over half of residents at nursing homes would opt to get the vaccine. At that level, officials believe, the virus cannot spread effectively.
BioNTech, the German drug maker that worked with Pfizer to develop a Covid-19 vaccine, will ship 100 million doses of the vaccine to China after it is authorized by the Chinese government, making it Beijing’s first foreign order of an inoculation against the disease.
The 100 million doses would be an initial shipment, BioNTech and its Chinese partner, Shanghai Fosun Pharmaceutical, said in a statement on Wednesday. They did not say how many more doses would be sent.
“This joint development effort with Fosun Pharma is a testament to the importance of global cooperation and reflects our strategy to supply our vaccine globally,” said Ugur Sahin, BioNTech’s chief executive and co-founder.
The companies did not say when the Chinese government is expected to give regulatory approval to the vaccine, which was found to be more than 90 percent effective and is being administered in the United States and elsewhere.
A series of vaccine scandals in China have stoked fears in the country about the quality of domestically made vaccines. It is common for members of the rapidly growing middle class to choose foreign-made vaccines over Chinese ones.
If approved, the BioNTech deal would suggest that Beijing wants to ensure that many of its people would have access to a safe vaccine in case its own vaccine candidates fall through or are unable to meet domestic demand. So far, no Chinese vaccine maker has reported full efficacy data for any of the country’s vaccines, five of which are in late-stage testing.
One of them, developed by the state-owned company Sinopharm, has been fully approved by two countries that participated in trials, the United Arab Emirates and Bahrain. Both cited preliminary data showing that the vaccine is 86 percent effective, exceeding the 50 percent threshold set by many governments. Sinopharm has not commented on either announcement.
In other global developments:
The start of the Australian Open will be delayed bythree weeks because of the pandemic, a schedule released by the men’s tennis tour revealed on Wednesday night. The year’s first Grand Slam tournament, which usually takes place in the last two weeks of January, will now start on Feb. 8, according to the ATP schedule.
Health officials in the Philippines warned on Thursday that the country’s progress in slowing the spread of the coronavirus could be reversed unless people “remain cautious and vigilant” during the holiday season. “Let us not squander our gains in this pandemic response,” they said in a statement, noting that a recent increase in cases in Manila could eventually overwhelm the health care system as happened during the peak of the country’s outbreak in August. On Wednesday, President Rodrigo Duterte asked Filipinos to limit holiday socializing and follow a new requirement to wear face shields in public at all times. “Just a bit more of sacrifice,” he said. “The vaccine is nearly here.”
Sidney Powell, a lawyer who was part of President Trump’s legal team, spread a conspiracy theory last month about election fraud. For days, she claimed that she would “release the Kraken” by showing voluminous evidence that Mr. Trump had won the election by a landslide.
But after her assertions were widely derided and failed to gain legal traction, Ms. Powell started talking about a new topic. On Dec. 4, she posted a link on Twitter with misinformation that said that the population would be split into the vaccinated and the unvaccinated and that “big government” could surveil those who were unvaccinated.
“NO WAY #America,” Ms. Powell wrote in the tweet, which collected 22,600 shares and 51,000 likes. “This is more authoritarian communist control imported straight from #China.”
Ms. Powell’s changing tune was part of a broader shift in online misinformation. As Mr. Trump’s challenges to the election’s results have been knocked down and the Electoral College has affirmed President-elect Joseph R. Biden Jr.’s win, voter fraud misinformation has subsided. Instead, peddlers of online falsehoods are ramping up lies about the Covid-19 vaccines.
Researchers said the spread had been amplified by far-right websites and a robust network of anti-vaccination activists like Robert F. Kennedy Jr. on platforms including Facebook, YouTube and Twitter.
The Metropolitan Transportation Authority has warned for months that the agency will be forced to make draconian cuts, including slashing New York City’s subway service 40 percent, as the pandemic plunged the nation’s largest public transit agency into its worst financial crisis.
But as Joseph R. Biden Jr. prepares to move into the White House, Congress in recent days seemed to be edging closer to reaching a compromise on a federal aid package that would likely provide $4 billion to the M.T.A., allowing the agency to avoid, for now, imposing its doomsday plan.
Patrick J. Foye, the chairman of the agency, said the M.T.A. continued to seek $12 billion in federal aid to help stabilize its finances, which have been decimated by a ridership that has rebounded to only 30 percent of pre-pandemic levels.
Beside huge cuts to subway service, the agency has also proposed slashing commuter rail service in half and laying off over 9,000 transit workers.
And early next year, the M.T.A. board is expected to approve 4 percent increases in fares and tolls that would take effect in the spring and generate more revenue for the 2021 budget, according to people familiar with the proposed plan who asked not to be identified before the board takes action.
Transportation advocates have urged Gov. Andrew M. Cuomo, who controls the M.T.A., and state lawmakers to identify new revenue streams — including raising the gas tax or creating a surcharge on nonessential items purchased online — to help the agency dig out of its financial hole without relying so heavily on future federal help.
The agency has already achieved $1 billion in savings by trimming administrative expenses, like reducing overtime and cutting consultant contracts, and borrowed $3.4 billion, the maximum amount allowed, from an emergency lending program provided by the Federal Reserve.
Transit officials have said they are hopeful that more relief could come under Mr. Biden, who is known as a fan of Amtrak, the national railroad, and has also signaled support for public transit systems.
As countries prepare to distribute hundreds of millions of Covid-19 vaccines — some of which require storage as cold as the South Pole in winter — the highly specialized operations of companies like PCI Pharma Services, which specializes in packaging and shipping drugs around the world, are in heavy demand. And Wall Street, which likes nothing better than a hot trade with the potential for big profits, is rushing to grab a piece of the action.
Investors were already snapping up shares of vaccine makers like Moderna and Pfizer, whose vaccine, developed with BioNTech, was introduced in the United States on Monday and requires an exceptionally low storage temperature of minus 70 Celsius.
Private equity firms and wealthy individual investors have also been seizing on smaller companies like PCI Pharma, whose cold-storage operations will play a crucial role in delivering Covid vaccines to the public.
Until recently, the temperature-controlled storage and shipping of pharmaceutical products, known as the “cold chain,” was a relatively sleepy corner of the health care industry. The technology to preserve animal-based cells and tissues by transporting them in cold conditions has been available since the 1950s, and certain breakthroughs in cancer research in the last decade increased demand for cold-chain transportation.
But the virus and the vaccines poised to combat it have brought new attention to cold-chain delivery systems.
In October, Blackstone, the private equity giant, invested $275 million in Cryoport, which specializes in shipping sensitive medical materials at freezing temperatures. Investors have also been bullish on Ember, the beverage-heating company that has developed a refrigerated medical shipping box with built-in GPS and already counts two Jonas Brothers and the Brooklyn Nets forward Kevin Durant as shareholders.
Shares of Cryoport are up more than 180 percent this year. Already, the company has transported temperature-sensitive materials involved in 26 Covid vaccines and treatments and has a long-term partnership with McKesson, a distributor of medical supplies that has been tapped by the U.S. government to manage domestic vaccine distribution.
Ram M. Jagannath, a senior managing director at Blackstone, said that the cell and gene-based therapies market where the company operates is likely to grow at an annualized rate of 50 percent for the next five years. “The current pandemic has only served to increase interest and investment in these potentially lifesaving therapies,” Mr. Jagannath said. “We invested in this for the long run.”